Therapeutic Advances in Urology Q1 Unclaimed
Therapeutic Advances in Urology is a journal indexed in SJR in Urology with an H index of 44. It is an CC BY-NC Journal with a Single blind Peer Review review system, and It has a price of 1350 €. The scope of the journal is focused on urology, clinical urology, pharmacology. It has an SJR impact factor of 0,941 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 0,941.
Type: Journal
Type of Copyright: CC BY-NC
Languages: English
Open Access Policy: Open Access
Type of publications:
Publication frecuency: -
1350 €
Inmediate OANPD
Embargoed OA- €
Non OAMetrics
0,941
SJR Impact factor44
H Index39
Total Docs (Last Year)148
Total Docs (3 years)1463
Total Refs461
Total Cites (3 years)142
Citable Docs (3 years)3.62
Cites/Doc (2 years)37.51
Ref/DocOther journals with similar parameters
European Urology Q1
Neuro-Oncology Q1
JAMA Neurology Q1
Nature Reviews Neurology Q1
Molecular Neurodegeneration Q1
Compare this journals
Aims and Scope
Best articles by citations
Experience in the use of collagenase clostridium histolyticum in the management of Peyronie's disease: current data and future prospects
View moreClinical experience with everolimus in the second-line treatment of advanced renal cell carcinoma
View morePrevention of recurrent urinary tract infections: bridging the gap between clinical practice and guidelines in Latin America
View moreA prospective, observational grouped analysis to evaluate the effect of triptorelin on lower urinary tract symptoms in patients with advanced prostate cancer
View moreCurrent trends in percutaneous nephrolithotomy: an internet-based survey
View moreErectile preservation following radical prostatectomy
View moreA prospective, randomized comparative study of monopolar transurethral resection of the prostate versus photoselective vaporization of the prostate with GreenLight 120-W laser, in prostates less than 80cc
View moreNon-invasive management of primary phosphodiesterase type 5 inhibitor failure in patients with erectile dysfunction
View moreTargeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinoma
View moreMetabolomics analysis of blood identifies potential biomarkers and possible treatment targets for nocturia
View moreCytoreductive nephrectomy and its role in the present-day period of targeted therapy
View moreOutcomes of adult urethroplasty with commercially available acellular matrix
View moreSterile pyuria: a forgotten entity
View moreSerenoa repens extract in the treatment of benign prostatic hyperplasia
View moreSites of disease as predictors of outcome in metastatic renal cell carcinoma patients treated with first-line sunitinib or sorafenib
View moreThe efficacy of mirabegron in the treatment of urgency and the potential utility of combination therapy
View moreAvanafil for the treatment of erectile dysfunction: initial data and clinical key properties
View moreLaparoendoscopic single-site pyeloplasty
View moreEfficacy of triptorelin pamoate 11.25 mg administered subcutaneously for achieving medical castration levels of testosterone in patients with locally advanced or metastatic prostate cancer
View moreLaparoendoscopic single-site surgery in urology
View moreClinical factors affecting semen improvement after microsurgical subinguinal varicocelectomy: which subfertile patients benefit from surgery?
View moreCombined laparoscopic pyelolithotomy and endoscopic pyelolithotripsy for staghorn calculi: long-term follow-up results from a case series
View moreDegarelix monotherapy compared with luteinizing hormone-releasing hormone (LHRH) agonists plus anti-androgen flare protection in advanced prostate cancer: an analysis of two randomized controlled trials
View moreA magnetic resonance imaging-based prediction model for prostate biopsy risk stratification
View more
Comments